Waltham, MA

MassResearch, LLC

Diabetes Mellitus

Type 2 Diabetes Mellitus

Type 1 Diabetes Mellitus

Insulin icodec

LY900014

Novo Nordisk

Abbott

AgaMatrix

Insulet

Lilly

Mylan

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is an outpatient study testing different starting doses of insulin in participants with type 2 diabetes. Participants will manage their diabetes using the Omnipod M System. The system is comprised of an Omnipod M Pod, an Omnipod M Controller, and will be used with a Dexcom G6 continuous glucose monitoring sensor (CGM). The main objectives of the study are to evaluate the safety and tolerability of different starting doses of insulin using the Omnipod M System.

There is a precursory evaluation before the main, randomized trial. Participation in the precursory evaluation could last up to 12 weeks and participation in the randomized trial could last up to 6 weeks. During both the evaluation and the randomized trial, participants will manage their diabetes using the Omnipod M System in Automated Mode.

An optional 12-weeks of continued Omnipod M System use is available upon completion of the randomized trial.

Simplified Onboarding in Adults With Type 2 Diabetes

MassResearch, LLC | Waltham, MA

Site insights

Work at this site?

Active trials

Simplified Onboarding in Adults With Type 2 Diabetes (SIMPLEUSE)

Trial sponsors